Chidambar Sandeep Kulkarni, CEO at Tourmaline Bio (NASDAQ:TRML), reported a large acquisition of company stock options on October 24, according to a new SEC filing.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Kulkarni, CEO at Tourmaline Bio, a company in the Health Care sector, was just awarded stock options worth 783,001 shares of TRML. The options give Kulkarni the right to buy the company's stock at $8.41 per share.

Tourmaline Bio shares are trading up 5.71% at $10.0 at the time of this writing on Tuesday morning. Since the current price is $10.0, this makes Kulkarni's 783,001 shares worth $7,830,010.

Now trade stocks online ...

Full story available on Benzinga.com